GLP-1 drugs may cut risk of leukemia and lymphoma in type 2 diabetes patients
Source: News-Medical.Net
Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 diabetes patients, especially compared to insulin.
The study also highlights GLP-1RAs’ potential as a cancer-protective treatment, independent of glucose control.
Could a diabetes drug slash your cancer risk? New research shows GLP-1 receptor agonists may protect patients with type 2 diabetes from deadly blood cancers—beyond just managing blood sugar.
Glucagon-like peptide 1 (GLP-1, 7-36) molecule — a potent a… [4886 chars]